bluebird bio (BLUE) Stock Price: Why It Increased 21.14%

By Amit Chowdhry ● Jun 8, 2022
  • The stock price of bluebird bio Inc (NASDAQ: BLUE) increased by 21.14% in the previous trading session. This is why.

The stock price of bluebird bio Inc (NASDAQ: BLUE) increased by 21.14% in the previous trading session. Investors responded positively to bluebird bio announcing that the U.S. Food and Drug Administration (FDA) posted briefing documents for the FDA Cellular, Tissue and Gene Therapies Advisory Committee Meeting to review elivaldogene autotemcel (eli-cel) for early active cerebral adrenoleukodystrophy (CALD) in patients without a matched sibling donor and betibeglogene autotemcel (beti-cel) for the treatment of people with β-thalassemia who require regular red blood cell transfusions. The advisory committee meeting is going to take place June 9-10, 2022. 

Plus the Prescription Drug User Fee Act (PDUFA) goal dates for a decision on approval of beti-cel for people with β-thalassemia who require regular red blood cell transfusions and eli-cel for patients with early active CALD without a matched sibling donor are August 19, 2022, and September 16, 2022, respectively.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.